Michelle Xia (Xia Yu)
Michelle Xia founded Akeso, the Zhongshan company whose bispecific antibody ivonescimab was the first drug to beat pembrolizumab in a head-to-head trial.
Overview
A returnee antibody scientist who founded Akeso in 2012 and built the Tetrabody platform behind cadonilimab (PD-1 x CTLA-4, approved 2022), ivonescimab (PD-1 x VEGF, approved 2024, HARMONi-2 win over pembrolizumab) and penpulimab (FDA approved 2025); licensed ivonescimab's Western rights to Summit Therapeutics for $500 million upfront.
Pages like this
not linked directly; found by shared links- PersonQing Zhou
Shares HARMONi-2, Ivonescimab and the tag china.
- PersonWenfeng Fang
Shares HARMONi-A, Akeso, Ivonescimab.
- TrialHARMONi-3
Shares HARMONi-A, Ivonescimab.
- CompanySummit Therapeutics
Shares HARMONi-A, Ivonescimab.
- TrialCOMPASSION-16 / AK104-303
Shares Cadonilimab, Akeso.
- PersonCaicun Zhou
Shares HARMONi-2, Akeso, Ivonescimab.
- Key paperHARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer
Shares Akeso, Ivonescimab.
- InstitutionNational Medical Products Administration / Center for Drug Evaluation
Shares Akeso, Ivonescimab.